secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-07-09T20:09:56+00:00
Accession:  0001437749-26-023200
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed completes enrollment in Phase 2a study of neflamapimod for nfvPPA
--------------------------------------------------------------------------

- Enrolled 25 participants; interim biomarker data to be presented at CTAD conference Nov 16-19, 2026.
- First clinical data expected in Q1 2027; study includes 24-week treatment plus 12-week placebo-controlled extension.
- Nature Neuroscience publication shows p38α inhibition rescues axonal transport deficits in tau-related FTD models.
- No approved treatments for nfvPPA in US or EU; neflamapimod granted Orphan Drug Designation for FTD in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926023200/0001437749-26-023200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926023200/crvo20260709_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-023200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer